CDT
Price
$0.13
Change
-$0.01 (-7.14%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
111.52K
21 days until earnings call
Intraday BUY SELL Signals
NRXP
Price
$2.40
Change
-$0.23 (-8.75%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
113.87M
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CDT vs NRXP

CDT vs NRXP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CDT vs. NRXP commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDT is a StrongBuy and NRXP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CDT with price predictions
Oct 21, 2026

CDT in upward trend: price may jump up because it broke its lower Bollinger Band on September 17, 2026

CDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 39 cases where CDT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CDT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.001) is normal, around the industry mean (2.988). P/E Ratio (-0.000) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. CDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NRXP with price predictions
Oct 21, 2026

NRXP's Indicator enters downward trend

The Aroon Indicator for NRXP entered a downward trend on October 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 298 similar instances where the Aroon Indicator formed such a pattern. In 290 of the 298 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for NRXP turned negative on September 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 33 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NRXP's RSI Indicator exited the oversold zone, 30 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 66 cases where NRXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

NRXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRXP's P/B Ratio (-669.811) is very low in comparison to the industry average of (2.988). P/E Ratio (-5.157) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (29.851) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. NRXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
NRXP: Fundamental Ratings
NRXP
OUTLOOK RATING
1..100
64
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
80
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CDTNRXP
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
Bearish Trend 7 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CDT: $0.14 vs. NRXP: $2.63)
Brand notoriety: CDT and NRXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDT: 301% vs. NRXP: 73%
Market capitalization -- CDT: $100.27K vs. NRXP: $103.91M
CDT [@Biotechnology] is valued at $100.27K. NRXP’s [@Biotechnology] market capitalization is $103.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDT’s FA Score shows that 1 FA rating(s) are green while NRXP’s FA Score has 2 green FA rating(s).

  • CDT’s FA Score: 1 green, 4 red.
  • NRXP’s FA Score: 2 green, 3 red.
According to our system of comparison, both CDT and NRXP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDT’s TA Score shows that 1 TA indicator(s) are bullish while NRXP’s TA Score has 3 bullish TA indicator(s).

  • CDT’s TA Score: 1 bullish, 2 bearish.
  • NRXP’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, NRXP is a better buy in the short-term than CDT.

Price Growth

CDT (@Biotechnology) experienced а -39.71% price change this week, while NRXP (@Biotechnology) price change was +1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

CDT is expected to report earnings on Nov 12, 2026.

NRXP is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CDT
Daily Signal:
Gain/Loss:
NRXP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CDT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDT has been loosely correlated with SLXN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CDT jumps, then SLXN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDT
1D Price
Change %
CDT100%
-8.99%
SLXN - CDT
44%
Loosely correlated
+7.28%
CMND - CDT
32%
Poorly correlated
-3.10%
PEPG - CDT
32%
Poorly correlated
-5.23%
NRXP - CDT
27%
Poorly correlated
+0.38%
LTRN - CDT
25%
Poorly correlated
+4.28%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TOP15.630.72
+4.83%
TOP Financial Group Limited
MAGN11.200.13
+1.17%
Magnera Corporation
NTRSO18.30N/A
N/A
Northern Trust Corp
DAR59.09-0.13
-0.22%
Darling Ingredients
YIBO0.99-0.05
-4.81%
Planet Image International Limited